Product Description
Mechanisms of Action: Imaging Agent
Novel Mechanism: No
Modality: Diagnostic Agent
Route of Administration: Oral,Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Stanford University
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Thyroid Cancer
Phase 1: Breast Cancer|Thyroid Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT00199862 | N/A |
Active, not recruiting |
Colorectal Cancer |
2027-06-01 |
|
| NCT03647358 | P1 |
Recruiting |
Thyroid Cancer |
2026-08-01 |
|
| DIAMONDT | P2 |
Active, not recruiting |
Thyroid Cancer |
2019-01-27 |
|
| rhTSH | N/A |
Terminated |
Thyroid Cancer |
2018-10-01 |